Abstract:The development of anti-tuberculosis (anti-TB) drugs has become a challenging task in medicinal chemistry. This is because Mycobacterium tuberculosis (TB), the pathogen that causes tuberculosis, has an increasing number of drug-resistant strains, and existing medication therapies are not very effective. This resistance significantly demands new anti-TB drug profiles. Here, we present the design and synthesis of a number of hybrid compounds with previously known anti-mycobacterial moieties attached to quinoxaline, quinoline, tetrazole, and 1,2,4-oxadiazole scaffolds. A convenient ultrasound methodology was employed to attain spiroquinoxaline-1,2,4-oxadiazoles via [3 + 2] cycloaddition of quinoxaline Schiff bases and aryl nitrile oxides at room temperature. This approach avoids standard heating and column chromatography while producing high yields and shorter reaction times. The target compounds 3a-p were well-characterized, and their in vitro anti-mycobacterial activity (anti-TB) was evaluated. Among the screened compounds, 3i displayed promising activity against the Mycobacterium tuberculosis cell line H37Rv, with an MIC99 value of 0.78 μg/mL. However, three compounds ( 3f , 3h , and 3o ) exhibited potent activity with MIC99 values of 6.25 μg/mL. To further understand the binding interactions, the synthesized compounds were docked against the tuberculosis protein 5OEQ using in silico molecular docking. Moreover, the most active compounds were additionally tested for their cytotoxicity against the RAW 264.7 cell line, and the cytotoxicity of compounds 3f , 3h , 3i , and 3o was 27.3, 28.9, 26.4, and 30.2 μg/mL, respectively. These results revealed that the compounds 3f , 3h , 3i , and 3o were less harmful to humans. Furthermore, the synthesized compounds were tested for ADME qualities, and the results suggest that this series is useful for producing innovative and potent anti-tubercular medicines in the future.

A Microporous Roust La(III)-organic Framework for Cyanosilylation Reactions and Treatment Effect on Tuberculosis by Activating the PI3K-AKT Signaling Pathway in Immune Cells

A Microporous Zn(II)–MOF for Solvent-Free Cyanosilylation and Treatment Effect Against Bacterial Infection on Burn Patients Via Inhibiting the Staphylococcus aureus Biofilm Formation

A luminescent Zn(II)-Containing Complex: Selective Sensing of Cr(VI) Anion and Application Values on Tuberculosis Care Through Increasing the Antibacterial Response of Macrophages

A new porous Co(II)‐coordination polymer for the chemical fixation of CO 2 and treatment effect against tuberculosis by reducing the pckA expression in Mycobacterium tuberculosis

Design, synthesis, biological evaluation study of spirocyclic POM analogues as novel MmpL3 anti-tubercular agent

New Antitumor-Active Azole-Bridged Dinuclear Platinum(II) Complexes: Synthesis, Characterization, Crystal Structures, and Cytotoxic Studies.

RETRACTED: Porous Co-MOF for Cyanosilylation Reaction and Protective Effect in Child Bronchial Pneumonia by Reducing the Inflammatory Response and IL-12 Production in Immune Cells

Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs

Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities

Microwave-assisted synthesis of novel Ti/BTB-MOFs as porous anticancer and antibacterial agents

Design and synthesis of Thieno[3, 2- b ]pyridinone derivatives exhibiting potent activities against Mycobacterium tuberculosis in vivo by targeting Enoyl-ACP reductase

Integrating computational and experimental approaches in discovery and validation of MmpL3 pore domain inhibitors for specific labelling of Mycobacterium tuberculosis

A novel synergistic enzyme-antibiotic therapy with immobilization of mycobacteriophage Lysin B enzyme onto Rif@UiO-66 nanocomposite for enhanced inhaled anti-TB therapy; Nanoenzybiotics approach

Design, synthesis and biological evaluation of diamino substituted cyclobut-3-ene-1,2-dione derivatives for the treatment of drug-resistant tuberculosis

Structure-based Design of Anti-Mycobacterial Drug Leads That Target the Mycolic Acid Transporter MmpL3

A New Tb(III) MOF for Selective Detection of Cu2+ Ion and Prevention Ability Against Staphylococcus aureus Biofilm Formation on Patients with Renal Failure

Cu(II)-Containing Metal–Organic Framework with 1D Hexagonal Channels for Cyanosilylation Reaction and Anticancer Activity on Osteosarcoma Cells

Design, synthesis, anti-mycobacterial activity, molecular docking and ADME analysis of spiroquinoxaline-1,2,4-oxadiazoles via [3 + 2] cycloaddition reaction under ultrasound irradiation

Highly potent bactericidal activity of porous metal-organic frameworks

A Porous CoII-MOF for CO2Cycloaddition and the Protective Effect Againststaphylococcus Aureussystemic Infection in the Department of Ultrasound

Macrophage targeted graphene oxide nanosystem synergize antibiotic killing and host immune defense for Tuberculosis Therapy